

New Developments in Desensitization Protocols: Is There a Standard of Care?

Robert A. Montgomery, M.D., D.Phil.

Professor of Surgery

Director of the NYU Langone Transplant Institute

Disclosures:

Served on Advisory Boards for Genentech Scientific/ROCHE, True North/iPierian, Alexion, Novartis, and Hansa Medical

Received consulting fees from OrbidMed, GuidePoint Global, Sucampo, Astellas, and Shire

Received research grants from Immune Tolerance Network, ViroPharma, Hansa, and Alexion.


Involved in clinical trial design for some of the off label drugs I will be discussing:

anti-CD20

IdeS


C5 inhibitor

AMR Is Associated With A Poor Outcome¹




¹Lefaucheur C et al. *J Am Soc Nephrol*. 2010.21:1398-1406.

Compare Apples To Apples



- Outcomes of desensitization protocols need to be compared to options that are actually available to the patient
- For a patient with a CPRA of 100% receiving a compatible kidney has not been a realistic option and this should not be the reference intervention

Survival Advantage of Desensitization Over Remaining on the Waitlist¹



No. at Risk

Recipients of incompatible transplants	1025	958	832	584	327
Waiting-list-or-transplant control group	5125	4546	3673	2493	1414
Waiting-list-only control group	5125	4141	3024	1810	916


DSA Fate By Specificity After Plasmapheresis¹

Specific	Eliminated	Persistent
cl	74%	26%
cII (DR, DQ)	56%	44%
DR51, 52, 53	20%	80%
Isoagglutinins	0%	100%

¹Zachary, et al. Transplantation. 2003 Nov 27;76(10):1519-25.

Graft survival Is Related To DSA Strength


Death-Censored Graft Survival by Antibody Strength



Number at risk



CDC+	83	64	57	54	48	42	37	24	20	14	5
FCXM+	146	121	105	87	64	49	37	27	20	14	12
Luminex+	81	61	55	41	27	22	13	11	5	1	0

Risk Of AMR In Desensitized Patients By HLA DSA Strength¹




¹Montgomery RA et al. unpublished.

Marked Survival Advantage of Desensitization vs. Other Available Options Even At CDC+ Strength¹




¹Montgomery et al., N ENGL J MED 365;4 NEJM.ORG JULY 28, 2011

Combining Paired Donation With Desensitization




Montgomery et al. *JAMA*. 2005; 294:1655.

Point Changes: Sensitization



CPRA 99-100% recipient “≈2 yrs bolus effect”




SRTR

Transplants to CPRA 99-100% rose sharply after KAS; tapered to 10%

KAS Priority For Highly Sensitized Candidates: Hopkins Data


- Current Waiting list (active & inactive): 1338 patients
- CPRA 98-100%: 164 candidates (12%)
- Since new KAS: CPRA \geq 98%
 - DDRT 66 patients transplanted
 - 64/66 of them had CPRA 100%
 - LDRT HLA incompatible 25 patients (normally > 50)

Competition For The Same Rare Genotypes Results In A Low KPD Match Rate¹



¹Montgomery/Jackson. Curr Opin Organ Transplant. 2011. 16(4):439-43.

Plasmapheresis Based SOC Desensitization for HLAi LD Recipients ^{1,2}



Goal is a (–) Cyto XM

Goal is a (–) Flow XM

1. Montgomery RA. *Transplantation* 2000;70:887.
2. Montgomery RA. *Am J Transplant*. 2010;10:449.

*For repeat mismatches and CDC+XM

Does Rituximab Prevent An Anamnestic Response¹

Post-Transplant Antibody Production to Antigen With Elevated B-Cell Frequencies^a

Made Antibody to Tetramer Antigen ^b	Treated With Rituximab		$\chi^2_1 = 16.2$ $P = .00006$
	Yes	No	
Yes	0	13	
No	10	3	

- Tetramers used to determine the frequencies of B cells with HLA specificities that are not producing soluble antibody
- Tetramers are available only for a limited number of HLA molecules


^a There was not detectable antibody to the tested tetramer antigen prior to transplantation. ^b Made antibody to the tetramer antigen after transplantation.

ORIGINAL ARTICLE


Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation

Ashley A. Vo, Pharm.D., Marina Lukovsky, Pharm.D., Mieko Toyoda, Ph.D., Jennifer Wang, M.D., Nancy L. Reinsmoen, Ph.D., Chih-Hung Lai, Ph.D., Alice Peng, M.D., Rafael Villicana, M.D., and Stanley C. Jordan, M.D.

80% Transplant rate and 94% graft survival



Outcomes of IVIg Desensitization With and Without Anti-CD20¹



Vo et al. ATC 2013 Abstract #841

Therapies and Intervention For HLA DSA

The Tackle Box


Standard of Care (SOC)

- Plasmapheresis
- Immunoabsorption
- IVIg (high or low dose)
- Steroids or ATG
- [Rituximab]
- Splenectomy

Add-ons to SOC

- Anti-CD20
- Complement Inhibitors (eculizumab and C1INH)
- Proteosomal Inhibitors
- Tocilizumab (anti-IL-6R)
- IdeS
- Splenic Irradiation

Classical Complement Pathway in Acute AMR in Sensitized KTRs¹



^a FDA approved for PNH and aHUS.

AMR, antibody-mediated rejection; DAF, decay-accelerating factor; DSAs, donor-specific antibodies, HLA, human leukocyte antigen; Y-CVF, Yunnan-cobra venom factor.

¹Stegall MD et al. *Nat Rev Nephrol.* 2012;8:670–678.

Positive Crossmatch Kidney Transplant Recipients Treated With Eculizumab: Outcomes Beyond 1 Year

L. D. Cornell¹, C. A. Schinstock²,
M. J. Gandhi³, W. K. Kremers² and
M. D. Stegall^{2,*}

AJT (2015) 5:1293-1302

Decreased ABMR 6.7% vs. 43.8% but no effect on TG at 2 years

Transplant Glomerulopathy in Controls versus Eculizumab			
	3-4 months	1 year	2 years
Eculizumab*	0% (0/28)	26.7% (8/30)	45.4% (10/22)
Control	9.3% (4/43)	39.5% (15/38)	63.6% (21/33)
P-value	0.15	0.31	0.27

*Residual DSA was not removed after the transplant

IdeS characteristics in humans

- IdeS treatment inhibits Fc-mediated activities
 - IgG mediated CDC
 - IgG mediated ADCC
 - IgG mediated phagocytosis
- IdeS only cleaves IgG (not IgM, IgA, IgD or IgE)
- IdeS has selective species specificity (human & rabbit)
- IdeS cleaves all forms of IgG: free, bound to antigen and membrane bound (BCR)
- PK of IdeS
 - Alpha phase (distribution): 5 h
 - Beta phase (elimination): 70 h
- IdeS is immunogenic and not novel to the immune system

IdeS: IgG-degrading enzyme of *Streptococcus pyogenes*

Highly specific for human IgG

$(ab')_2$



Glu-Leu-Leu-Gly²³⁶↓Gly-Pro


2 hrs

4 hrs


*

***Single-cleaved IgG (sclgG)**

IdeS Effect on Class I Antibody In A Sensitized Patient




IdeS Effect on Class II Antibody In A Sensitized Patient



Trouble in paradise: IgG rebounds by day 14 and patient cannot be given more than 2 doses because of antibody formation

HLA Incompatible Donor IdeS Protocol



IdeS Desensitization: NYU Patient #2

Pre-IdeS

2 hr Post-IdeS

DONOR FLOW CROSSMATCH	Flow Cytometry	
	Recipient Untreated Serum	
	4/6/2017	4/7/2017
Donor B Cell	Pos (275)	Pos (133)
Donor T Cell	Pos (264)	Pos (110)

45 yo patient with 20 years on HD and 100% CPRA.
We eliminated as unacceptable all HLA ab with MFI < 20,000
and she still had a 100% CPRA. Received an import offer
for a 41 yo DBD with a + CDC XM.

Pre-IdeS

RELATION	A* B O	HLA TYPING																			
		Typing results are the most probable serological equivalents for low/intermediate molecular (DNA) testing. NT: Not typed for the HLA locus.																			
		A		B		Bw 4 6		C		DR B1 B1		DR B3 B4 B5			DQ B1 B1		DP B1 B1		DQA A1 A1		
SELF	O	2	33	53		+		4		7	8		53			2	7	NT	NT	02	04
DECEASED	O	1	2	27	38	+		9	12	8	13	52				4	6	02:01	03:01	01	04:01
Class I & II Ab: 6/2017 0528	Peak MFI Values	24,103	0	23,721	5,985			23,107	21,625	0	749	1,531				321	4,898	*	*	*	*
A serum is scored POSITIVE for an antigen if the MFI value is greater than or equal to 2000.																					

2 hr Post-IdeS

A* B O	HLA TYPING																				
	Typing results are the most probable serological equivalents for low/intermediate molecular (DNA) testing. NT: Not typed for the HLA locus.																				
	A		B		Bw 4 6		C		DR B1 B1		DR B3 B4 B5			DQ B1 B1		DP B1 B1		DQA A1 A1			
O	2	33	53		+		4		7	8		53			2	7	NT	NT	02	04	
O	1	2	27	38	+		9	12	8	13	52				4	6	02:01	03:01	01	04:01	
Peak MFI Values	10,271	0	7,736	662			5,530	4,532	0	3	10				0	530	*	*	*	*	
A serum is scored POSITIVE for an antigen if the MFI value is greater than or equal to 2000.																					

48 hrs Post-IdeS

RELATION	A* B O	HLA TYPING																		
		Typing results are the most probable serological equivalents for low/intermediate molecular (DNA) testing. <u>NT: Not typed for the HLA locus.</u>																		
		A		B		Bw 4 6		C		DR B1 B1		DR B3 B4 B5			DQ B1 B1		DP B1 B1		DQA A1 A1	
SELF	O	2	33	53		+		4		7	8		53		2	7	NT	NT	02	04
DECEASED	O	1	2	27	38	+		9	12	8	13	52			4	6	02:01	03:01	01	04:01
Anti-HLA I & II Ab: 9/2017 0780	Peak MFI Values	3,318	0	2,358	18			1,127	715	0	0	0			0	32	0	0	32	0
A serum is scored POSITIVE for an antigen if the MFI value is greater than or equal to 2000.																				

5 days Post-IdeS

RELATION	A* B O	HLA TYPING																		
		Typing results are the most probable serological equivalents for low/intermediate molecular (DNA) testing. <u>NT: Not typed for the HLA locus.</u>																		
		A		B		Bw 4 6		C		DR B1 B1		DR B3 B4 B5			DQ B1 B1		DP B1 B1		DQA A1 A1	
SELF	O	2	33	53		+		4		7	8		53		2	7	NT	NT	02	04
DECEASED	O	1	2	27	38	+		9	12	8	13	52			4	6	02:01	03:01	01	04:01
Anti-HLA I & II Ab: 10/2017 0903	Peak MFI Values	2,092	0	1,517	0			602	308	0	0	0			0	0	0	0	0	0
A serum is scored POSITIVE for an antigen if the MFI value is greater than or equal to 2000.																				

Acknowledgements:

Lorraine Racusen

Mark Haas

Karen King

Andrea Zachary

Susie Leffell

Donna Lucas

Julie Houp

Pail Sikorski

Dorry Segev

Chris Sonnenday

Dan Warren

Chris Simpkins

Bonnie Lonze

Nabil Dagher

Andy Singer

Andrew Cameron

Susanna Nazarian

Niraj Desai

Rachel Marino

Carrie Chamberlain

Elaina Burney

Tara Webb

Nada Alachkar

Karl Wormer

Sharon Fryar-Jones

Julie Shamberger

Cindy Grisbach

Nicole Ali

Vasishta Tatapudi

Janet Hiller

Jennie Rickard

Keith Melancon

Mike Tan

Warren Maley

James Burdick

Milagros Samaniego

Edward Kraus

Hamid Rabb

Jayne Locke

Brigitte Sullivan

Mary Jo Holechek

Diane Lepley

Nikki Lawson

Kathy Dane

Jayne Locke

Matt Cooper

Lloyd Ratner

Julie Dennison

Lauren Kucirka

